0000899243-23-011780.txt : 20230426 0000899243-23-011780.hdr.sgml : 20230426 20230426193045 ACCESSION NUMBER: 0000899243-23-011780 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220106 FILED AS OF DATE: 20230426 DATE AS OF CHANGE: 20230426 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FRATES JAMES M CENTRAL INDEX KEY: 0001235598 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 23851335 MAIL ADDRESS: STREET 1: 88 SIDNEY ST CITY: CAMBRIDGE STATE: MA ZIP: 021394136 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2022-01-06 2022-01-06 0 0001658551 Amylyx Pharmaceuticals, Inc. AMLX 0001235598 FRATES JAMES M C/O AMYLYX PHARMACEUTICALS, INC. 43 THORNDIKE STREET CAMBRIDGE MA 02141 0 1 0 0 Chief Financial Officer Series C-1 Preferred Stock Common Stock 19482 I By Trust This amendment on Form 3/A to the Form 3 originally filed on January 6, 2022 (the "Original Form 3") is being filed solely to include 19,482 shares of Series C-1 Preferred Stock held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee, which were inadvertently omitted from the Original Form 3. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose. Each share of Series C-1 Preferred Stock is convertible on a one-for-one basis into Common Stock at any time at the election of the Reporting Person and will automatically convert upon the closing of the Issuer's initial public offering into the number of shares of the Issuer's Common Stock shown in column 3 without payment or further consideration. The Series C-1 Preferred Stock has no expiration date. /s/ Joshua B. Cohen, as Attorney-in-Fact for James Frates 2023-04-26